Purple Biotech PE Ratio 2014-2021 | PPBT

Current and historical p/e ratio for Purple Biotech (PPBT) from 2014 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Purple Biotech PE ratio as of September 24, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Purple Biotech PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-09-24 4.79 inf
2021-06-30 4.88 0 0.00
2021-03-31 4.13 0 0.00
2020-12-31 3.81 0 0.00
2020-06-30 11.10 0 0.00
2019-12-31 7.80 0 0.00
2019-06-30 9.40 0 0.00
2018-12-31 6.60 0 0.00
2018-06-30 26.40 0 0.00
2017-12-31 22.80 0 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.127B $0.001B
Purple Biotech Ltd. is a clinical-stage company focusing on therapies to overcome tumor immune evasion and drug resistance. The Company's oncology pipeline includes NT219 and CM24. Purple Biotech Ltd., formerly known as Kitov Pharma Ltd., is based in TEL AVIV, Israel.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71